These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16532534)

  • 1. Characterization of a novel impurity in bulk drug of lisinopril by multidimensional NMR technique.
    Wang DH; Pei SF; Zhou MH; Sun CR; Pan YJ
    J Zhejiang Univ Sci B; 2006 Apr; 7(4):310-3. PubMed ID: 16532534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a new impurity in lisinopril.
    Shinde V; Trivedi A; Upadhayay PR; Gupta NL; Kanase DG; Chikate R
    J Pharm Biomed Anal; 2007 Jan; 43(1):381-6. PubMed ID: 16926080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel trace-level impurity in lisinopril using multi-stage mass spectrometry.
    Pei S; Wang D; Sun C; Pan Y
    Eur J Mass Spectrom (Chichester); 2006; 12(2):121-7. PubMed ID: 16723753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of impurities in the bulk drug lisinopril by liquid chromatography/ion trap spectrometry.
    Zhu PX; Wang DH; Sun CR; Shen ZQ
    J Zhejiang Univ Sci B; 2008 May; 9(5):385-90. PubMed ID: 18500778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a trace colored impurity in drug substance by preparative liquid chromatography and mass spectrometry.
    Wang P; Shi YJ; Helmy R; Reamer R; Vailaya A
    Rapid Commun Mass Spectrom; 2005; 19(24):3749-54. PubMed ID: 16308847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and structural identification of an impurity in fluconazole bulk drug substance.
    Dongre VG; Ghugare PD; Karmuse PP; Soudagar SR; Panda N; Kumar A
    J Pharm Biomed Anal; 2007 Nov; 45(3):422-9. PubMed ID: 17706390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, isolation and characterization of potential degradation product in risperidone tablets.
    Bharathi Ch; Chary DK; Kumar MS; Shankar R; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Jan; 46(1):165-9. PubMed ID: 17981421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and identification of a new impurity in mitoxantrone hydrochloride.
    Haiyan L
    Pharmazie; 2009 Jun; 64(6):376-9. PubMed ID: 19618673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate.
    Bharathi Ch; Prabahar KJ; Prasad ChS; Srinivasa Rao M; Trinadhachary GN; Handa VK; Dandala R; Naidu A
    Pharmazie; 2008 Jan; 63(1):14-9. PubMed ID: 18271296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.
    Saravanan M; Siva Kumari K; Pratap Reddy P; Naidu MN; Moses Babu J; Srivastava AK; Lakshmi Kumar T; Chandra Sekhar BV; Satyanarayana B
    J Pharm Biomed Anal; 2008 Nov; 48(3):708-15. PubMed ID: 18755563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of new impurity in didanosine.
    Srinivasa Rao DV; Srinivas N; Bharathi Ch; Prasad ChS; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Nov; 45(3):516-20. PubMed ID: 17624711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product.
    Mohan A; Hariharan M; Vikraman E; Subbaiah G; Venkataraman BR; Saravanan D
    J Pharm Biomed Anal; 2008 May; 47(1):183-9. PubMed ID: 18313249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and identification of a new impurity in lorazepam substance.
    Cepanec I; Mikuldas H; Litvić M; Vukusić I
    Pharmazie; 2001 Nov; 56(11):857-9. PubMed ID: 11817169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR.
    Sun C; Wu J; Wang D; Pan Y
    J Pharm Biomed Anal; 2010 Feb; 51(3):778-83. PubMed ID: 19864105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an unknown trace-level impurity in bulk drug of Seroquel by high-performance liquid chromatography combined with mass spectrometry.
    Xu H; Wang D; Sun C; Pan Y; Zhou M
    J Pharm Biomed Anal; 2007 Jun; 44(2):414-20. PubMed ID: 17420108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and relative response factor determination of process related impurity in Naproxen by nuclear magnetic resonance spectroscopy.
    Iqbal MY; Rao KM; Sridhar G; Raju PP; Deshpande GR; Babu JM
    J Pharm Biomed Anal; 2011 Nov; 56(3):484-90. PubMed ID: 21782369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of some potential impurities in ropinirole hydrochloride.
    Sahasrabuddhey B; Nautiyal R; Acharya H; Khyade S; Luthra PK; Deshpande PB
    J Pharm Biomed Anal; 2007 Mar; 43(4):1587-93. PubMed ID: 17207602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.